Santen Pharmaceutical

Eyevance is a provider of ophthalmic products and therapies intended to address unmet medical needs. The company's products target areas such as the anterior segment, posterior segment and glaucoma ailments, providing patients with optimal vision and a better quality of life.

Plano is a business focused on addressing the global rise of myopia, a condition affecting 1.5 billion people worldwide, which is projected to increase to 5 billion by 2050. The company has developed a science-based parental control application aimed at keeping children safe online while promoting eye health. Its software includes tools for eye health checks, myopia screening management, and educational workshops designed to combat the epidemic of myopia, particularly linked to the excessive use of smart devices among children. By providing resources and support, Plano seeks to empower individuals and families to take proactive steps in managing eye health and mitigating the impact of digital lifestyle habits.

QD Laser, Inc. specializes in the development and manufacturing of quantum dot semiconductor lasers and wafers, primarily using GaAs substrates. The company produces a variety of laser technologies, including picosecond short-pulse DFB lasers for precision processing and current injection-type lasers in green, yellow-green, and orange for biological applications. Additionally, QD Laser develops quantum dot laser arrays for silicon optical circuits and broadband gain chips for ophthalmic testing equipment. Their products are utilized in diverse sectors such as telecommunications, manufacturing, medicine, and consumer products, addressing applications in silicon photonics, sensing, and precision machining. Established in 2006 and headquartered in Kawasaki, Japan, QD Laser aims to enhance the performance of semiconductor lasers across various industries.

QD Laser, Inc. specializes in the development and manufacturing of quantum dot semiconductor lasers and wafers, primarily using GaAs substrates. The company produces a variety of laser technologies, including picosecond short-pulse DFB lasers for precision processing and current injection-type lasers in green, yellow-green, and orange for biological applications. Additionally, QD Laser develops quantum dot laser arrays for silicon optical circuits and broadband gain chips for ophthalmic testing equipment. Their products are utilized in diverse sectors such as telecommunications, manufacturing, medicine, and consumer products, addressing applications in silicon photonics, sensing, and precision machining. Established in 2006 and headquartered in Kawasaki, Japan, QD Laser aims to enhance the performance of semiconductor lasers across various industries.

International Biomedical Devices (IBMD) is an early-stage medical device company focused on ophthalmology innovations. At present, the company is leading the emerging, non-laser based, precision capsulotomy category through the development of a unique and much-needed new capsulotomy technology. It was founded in 2013 and is based in Charleston, South Carolina.

InnFocus is a biomaterials company, develops and provides products in ophthalmology. The company's product portfolio includes an intraocular lens for microincision surgery and an implantable device for glaucoma. The company was incorporated in 2003 and is based in Miami, Florida.

InnFocus is a biomaterials company, develops and provides products in ophthalmology. The company's product portfolio includes an intraocular lens for microincision surgery and an implantable device for glaucoma. The company was incorporated in 2003 and is based in Miami, Florida.

RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. Founded in 2009, RetroSense Therapeutics is headquartered in Ann Arbor, Michigan.

TearSolutions, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing innovative therapies for dry eye conditions. Founded in 2013, the company is advancing Lacripep, a synthetic peptide derived from the natural tear protein lacritin, aimed at treating dry eyes, particularly in patients with primary Sjögren's syndrome. Lacripep is designed to preserve the biological activity of natural tear components while promoting healing of the corneal surface and alleviating symptoms without irritation. Currently, the company is conducting phase II human clinical trials to further validate its approach. TearSolutions employs an outsourcing model for its operations, emphasizing efficiency and scalability in the development and production of its therapies.

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing treatments for serious eye diseases with the aim of restoring and preserving vision. Founded in 2011 and headquartered in Alpharetta, Georgia, the company specializes in a proprietary ocular microinjection platform that allows for targeted delivery of therapeutic products to specific compartments of the eye. This innovative approach includes the use of the SCS Microinjector for administering therapies directly into the suprachoroidal space, enabling a non-surgical, repeatable procedure. Among its product pipeline, Clearside is developing XIPERE, a triamcinolone acetonide injectable suspension for macular edema, and CLS-AX, an axitinib for suprachoroidal injection. The company is dedicated to advancing pharmacological therapies for sight-threatening conditions by ensuring precise and effective treatment delivery.

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing treatments for serious eye diseases with the aim of restoring and preserving vision. Founded in 2011 and headquartered in Alpharetta, Georgia, the company specializes in a proprietary ocular microinjection platform that allows for targeted delivery of therapeutic products to specific compartments of the eye. This innovative approach includes the use of the SCS Microinjector for administering therapies directly into the suprachoroidal space, enabling a non-surgical, repeatable procedure. Among its product pipeline, Clearside is developing XIPERE, a triamcinolone acetonide injectable suspension for macular edema, and CLS-AX, an axitinib for suprachoroidal injection. The company is dedicated to advancing pharmacological therapies for sight-threatening conditions by ensuring precise and effective treatment delivery.